Heterologous Vaccine Schedule Against Sars-CoV-2 with 2 Doses of Inactivated Virus and a Booster of mRNA BNT162b2 in Kidney Transplant Recipients
American Journal of Transplantation
; 22(Supplement 3):767, 2022.
Article
in English
| EMBASE | ID: covidwho-2063510
ABSTRACT
Purpose:
Emerging evidence suggests that 3 doses of SARS-CoV-2 mRNA vaccine enhance immunity in kidney transplant (KT) patients. However, few studies have focused on humoral response after inactivated virus-based vaccines. Here we report the results of humoral response in KT recipients in comparison with healthy control group after homologous and heterologous regimens with inactivated virus (Coronavac) and mRNA vaccine BNT162b2. Method(s) A multicenter prospective study was conducted. KT recipients received heterologous vaccine schedule (2 doses of Coronavac and a booster of mRNA BNT162b2, n= 136) or homologous (3 doses of BNT162b2 n=19). Healthy control group received 2 doses or Coronavac (n=67) or BNT162b2 (n=15). Serum IgG antibodies against Receptor Binding Domain of SARS-CoV-2 Spike protein were determined 30 and 40 days after last dose. Result(s) Seroconversion was 52.2% and 57,9% with heterologous and homologous vaccination schedules in KT, p=0.789, figure 1. Among KT patients with seroconversion, antibody levels against RBD of SARS-CoV-2 were [1012 (183-3111) and 603 (41-1255) BAU/mL, with heterologous and homologous schedule, respectively. Levels were higher in KT compared to heathy control with 2 doses of inactivated virus 308 (209-335), p=0.03 and lower than heathy control with 2 doses of BNT162b2 2638 (2608-3808) BAU/mL, p=0.001]. Conclusion(s) Seroconversion improves after a third dose with homologous or heterologous vaccine schedules. Among patients with seroconversion antibody levels were higher than in heathy control with two doses of inactivated virus. Measurement of antibody levels could help to improve vaccination policies.
adult; conference abstract; controlled study; drug therapy; female; human; human tissue; humoral immunity; kidney graft; major clinical study; male; multicenter study; nonhuman; prospective study; protein domain; receptor binding; seroconversion; Severe acute respiratory syndrome coronavirus 2; vaccination; virus inactivation; coronavac; endogenous compound; immunoglobulin G antibody; messenger RNA; RNA vaccine; tozinameran; virus spike protein
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
American Journal of Transplantation
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS